Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Carfilzomib, thalidomide, and dexamethasone is safe and effective in relapsed and/or refractory multiple myeloma: final report of the single arm, multicenter phase II ALLG MM018/AMN002 study.
Ninkovic S, Harrison SJ, Lee JJ, Murphy N, Lee JH, Estell J, Chen VM, Horvath N, Kim K, Eek R, Augustson B, Bang SM, Huang SY, Rajagopal R, Szabo F, Engeler D, Butcher BE, Mollee P, Durie B, Chng WJ, Quach H. Ninkovic S, et al. Among authors: estell j. Haematologica. 2024 Jan 18. doi: 10.3324/haematol.2023.284238. Online ahead of print. Haematologica. 2024. PMID: 38235519 Free article.
Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14).
Kalff A, Khong T, Ramachandran M, Ho PJ, Mollee P, D'Rozario J, Taylor K, Estell J, Norton S, Kemp R, Mitchell AJ, Reynolds J, Kennedy N, Quach H, Spencer A. Kalff A, et al. Among authors: estell j. Haematologica. 2022 Jan 1;107(1):321-325. doi: 10.3324/haematol.2021.278655. Haematologica. 2022. PMID: 34587718 Free PMC article. No abstract available.
Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma.
Plesner T, Harrison SJ, Quach H, Lee C, Bryant A, Vangsted A, Estell J, Delforge M, Offner F, Twomey P, Choeurng V, Li J, Hendricks R, Ruppert SM, Sumiyoshi T, Miller K, Cho E, Schjesvold F. Plesner T, et al. Among authors: estell j. Clin Hematol Int. 2023 Mar;5(1):43-51. doi: 10.1007/s44228-022-00023-5. Epub 2023 Jan 19. Clin Hematol Int. 2023. PMID: 36656461 Free PMC article.
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators. Palumbo A, et al. N Engl J Med. 2016 Aug 25;375(8):754-66. doi: 10.1056/NEJMoa1606038. N Engl J Med. 2016. PMID: 27557302 Free article. Clinical Trial.
Challenges associated with test dose pharmacokinetic predictions of high dose melphalan exposure in patients with multiple myeloma.
Nath CE, Grigg A, Rosser SPA, Estell J, Newman E, Tiley C, Ramanathan S, Ho SJ, Larsen S, Gibson J, Presgrave P, Shaw PJ, Trotman J. Nath CE, et al. Among authors: estell j. Eur J Clin Pharmacol. 2022 Dec;78(12):1911-1921. doi: 10.1007/s00228-022-03396-x. Epub 2022 Oct 7. Eur J Clin Pharmacol. 2022. PMID: 36205743 Free PMC article.
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR.
Mateos MV, Sonneveld P, Hungria V, Nooka AK, Estell JA, Barreto W, Corradini P, Min CK, Medvedova E, Weisel K, Chiu C, Schecter JM, Amin H, Qin X, Ukropec J, Kobos R, Spencer A. Mateos MV, et al. Among authors: estell ja. Clin Lymphoma Myeloma Leuk. 2020 Aug;20(8):509-518. doi: 10.1016/j.clml.2019.09.623. Epub 2019 Oct 9. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32482541 Free article. Clinical Trial.
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).
Landgren CO, Chari A, Cohen YC, Spencer A, Voorhees P, Estell JA, Sandhu I, Jenner MW, Williams C, Cavo M, van de Donk NWCJ, Beksac M, Moreau P, Goldschmidt H, Kuppens S, Bandekar R, Clemens PL, Neff T, Heuck C, Qi M, Hofmeister CC. Landgren CO, et al. Among authors: estell ja. Leukemia. 2020 Jul;34(7):1840-1852. doi: 10.1038/s41375-020-0718-z. Epub 2020 Feb 5. Leukemia. 2020. PMID: 32024950 Free PMC article. Clinical Trial.
Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study.
Bachy E, Seymour JF, Feugier P, Offner F, López-Guillermo A, Belada D, Xerri L, Catalano JV, Brice P, Lemonnier F, Martin A, Casasnovas O, Pedersen LM, Dorvaux V, Simpson D, Leppa S, Gabarre J, da Silva MG, Glaisner S, Ysebaert L, Vekhoff A, Intragumtornchai T, Le Gouill S, Lister A, Estell JA, Milone G, Sonet A, Farhi J, Zeuner H, Tilly H, Salles G. Bachy E, et al. Among authors: estell ja. J Clin Oncol. 2019 Nov 1;37(31):2815-2824. doi: 10.1200/JCO.19.01073. Epub 2019 Jul 24. J Clin Oncol. 2019. PMID: 31339826 Free PMC article. Clinical Trial.
Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants.
Trotman J, Fournier M, Lamy T, Seymour JF, Sonet A, Janikova A, Shpilberg O, Gyan E, Tilly H, Estell J, Forsyth C, Decaudin D, Fabiani B, Gabarre J, Salles B, Van Den Neste E, Canioni D, Garin E, Fulham M, Vander Borght T, Salles G. Trotman J, et al. Among authors: estell j. J Clin Oncol. 2011 Aug 10;29(23):3194-200. doi: 10.1200/JCO.2011.35.0736. Epub 2011 Jul 11. J Clin Oncol. 2011. PMID: 21747087
Formalising multidisciplinary peer review: developing a haematological malignancy-specific electronic proforma and standard operating procedure to facilitate procedural efficiency and evidence-based clinical practice.
Trotman J, Trinh J, Kwan YL, Estell JA, Fletcher J, Archer K, Lee K, Foo K, Curnow J, Bianchi A, Wignall L, Verner E, Gasiorowski R, Siedlecka E, Cunningham I. Trotman J, et al. Among authors: estell ja. Intern Med J. 2017 May;47(5):542-548. doi: 10.1111/imj.13302. Intern Med J. 2017. PMID: 27753208
29 results